Products Acarbose is commercially available in tablet form (Glucobay). It is usually combined with other agents such as metformin, insulin, or sulfonylureas to enhance the antidiabetic effect. Acarbose has been approved in many countries since 1986. Structure and properties Acarbose (C25H43NO18, Mr = 645.60 g/mol) is a pseudotetrasaccharide obtained from the bacterium by fermentation. It … Acarbose Effects and Side Effects
Effects Sulfonylureas (ATC A10BB) have antidiabetic, antihyperglycemic, and insulin secretagogue properties. Active Ingredients 1st generation: Tolbutamide, acetohexamide, tolazamide (all off-label). Chlorpropamide (Diabiformin, out of commerce). 2nd generation: Glibenclamide (Daonil, generic). Glibornuride (Glutril, off label). Glipizide (Glibenese, out of trade) Gliclazide (Diamicron /-MR, generic). 3rd generation: Glimepiride (Amaryl, generic). Cf. Diabetes mellitus type 2, glinides
Products The first agent in the GLP-1 receptor agonist group to be approved was exenatide (Byetta) in the United States in 2005 and in many countries and the EU in 2006. In the meantime, several other drugs have been registered (see below). These drugs are also known as incretin mimetics. They are commercially available as … GLP-1 Receptor Agonists
Products Exenatide is commercially available as an injectable (Byetta, Bydureon). It was approved in the United States in 2005 as the first agent in the GLP-1 receptor agonist group (Byetta). In many countries, the drug was registered a year later. The long-acting Bydureon Pen was approved in many countries in 2012, with additional approval as … Exenatide
Products Saxagliptin is commercially available in the form of film-coated tablets (Onglyza). It was approved in many countries after sitagliptin (Januvia) and vildagliptin (Galvus) as the 3rd active ingredient from the gliptins group in February 2010. Since 2012, two additional combination products with metformin have been registered (Duoglyze, Kombiglyze XR). Kombiglyze XR entered the market … Saxagliptin
Products Lixisenatide was approved as a subcutaneous solution for injection in the EU in 2012, in the United States in 2016, and in many countries in 2017 (Lyxumia). Lixisenatide is also combined with insulin glargine; see iGlarLixi (Suliqua). Structure and properties Lixisenatide is a peptide and GLP1 analog of 44 amino acids that, like exenatide, … Lixisenatide
Products Liraglutide was approved in many countries in 2009 as a solution for injection in a prefilled pen (Victoza). In 2014, a fixed-dose combination with insulin degludec was released (Xultophy); see IDegLira. In 2016, Saxenda was registered for the treatment of overweight and obesity. Its related successor, semaglutide, unlike liraglutide, only needs to be injected … Liraglutide
Products Metformin is commercially available in many countries in the form of film-coated tablets and has been available since 1960. In addition to the original Glucophage, numerous generics are available today. Metformin is often combined with various other antidiabetic drugs fix. It has been used medically since 1957. Other antidiabetic biguanides such as phenformin and … Metformin: Drug Effects, Side Effects, Dosage and Uses
Products Repaglinide is commercially available in tablet form (NovoNorm, generic). It was approved in many countries in 1999. Structure and properties Repaglinide (C27H36N2O4, Mr = 452.6 g/mol) is a meglitinide and carbamoylmethylbenzoic acid derivative without sulfonylurea structure. It is a white, odorless powder that is practically insoluble in water due to its lipophilicity. In drugs, … Repaglinide
Products Glibenclamide is commercially available in tablet form (Daonil, generics). It has been approved in many countries since 1970 and is also used in fixed combination with metformin (Glucovance). Structure and properties Glibenclamide (C23H28ClN3O5S, Mr = 494.0 g/mol) is a sulfonylurea. It exists as a white crystalline powder that is practically insoluble in water. Effects … Glibenclamide
Products Glibornuride was commercially available in tablet form (Glutril, originally Roche, later MEDA Pharma). It was approved in many countries since 1971. It was discontinued in 2019. Structure and properties Glibornuride (C18H26N2O4S, Mr = 366.48 g/mol) is a sulfonylurea. Effects Glibornuride (ATC A10BB04) has antihyperglycemic and antidiabetic properties. The effects are due to the promotion … Glibornuride
Products Gliclazide has been commercially available in sustained-release tablet form and approved in many countries since 1978. The sustained-release dosage forms entered the market in 2001. In addition to the original Diamicron MR, sustained-release generics have been available since 2008. Sales of the non-retarded Diamicron 80 mg were discontinued in 2012. Structure and properties Gliclazide … Gliclazide
